Effects of combination Ezetimibe and Rosuvastatin Versus Rosuvastatin Alone on pro-inflammation and endothelial function in Patients With ACS underging PCI

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012219

Enrollment

Unknown

Registered

2017-08-02

Start date

2017-08-01

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

Ezetimibe +Rosuvastatin:Patients receiving Ezetimibe 10 mg/day and Rosuvastatin 10 mg/day.

Rosuvastatin:Patients receiving Rosuvastatin 10 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years, male and female; 2. patients with unstable angina pectoris; 3. patients with non ST segment elevation myocardial infarction; 4. patients with ST segment elevation myocardial infarction

Exclusion criteria

Exclusion criteria: 1. Infectious diseases; 2. Malignant tumor; 3. Liver and kidney function obviously abnormal disease; 4. rheumatism immunity disease; 5. Hematological system diseases; 6. Intolerance or allergy to ezetimibe or rosuvastatin; 7. Pregnant or lactating women; 8. Not undergoing PCI treatment.

Design outcomes

Primary

Measure	Time frame
sPLA2-IIa;IL-1ß;VCAM-1;ICAM-1;	—

Countries

China

Contacts

Public ContactSong Zhiyuan

Department of Cardiology, Southwest Hospital, Third Military Medical University

zysong2010@126.com+86 13908327066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026